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 S2   
General Considerations  
 
 
(A) General Analytical Information. 
  Nuclear Magnetic Resonance spectra were recorded on a Bruker Avance 400 MHz instruments at 
ambient temperature. All 1H NMR spectra were measured in part per million (ppm) relative to the signal 
of tetramethylsilane (TMS) added into the deuterated chloroform (CDCl3, 0.00 ppm), or the signal of 
residual dichloromethane in deuterated dichloromethane (CD2Cl2, 5.32 ppm).1,2 Data for 1H NMR were 
reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qu = 
quintet, sex = sextet, m = multiplet, ovrlp = overlap, br = broad), coupling constants, and integration. All 
13C NMR spectra were reported in ppm relative to CDCl3 (77.16 ppm), CD2Cl2 (53.84 ppm), or DMSO-
d6 (39.52 ppm)1,2 and were obtained with complete 1H decoupling. All gas chromatography (GC) 
analyses were performed on a Perkin-Elmer Clarus 400 GC system with a FID detector. All gas 
chromatography-mass spectrometry (GC-MS) analyses were performed on an Agilent Technologies 
7890A GC system equipped with a 5975C MS detector. High-resolution mass spectra (HRMS) by 
electrospray ionization (ESI) method were performed at the EPFL ISIC Mass Spectroscopy Service with 
a Micro Mass QTOF Ultima spectrometer.  
 
 
(B) General Reagent Information. 
  Unless otherwise noted, all chemicals were used as received without further purifications. 
Dimethylformamide (DMF) was purified and dehydrated using a two-column solid-state purification 
system (Innovative Technology, NJ, USA) and transferred to the glove box without exposure to air. 4,4’-
Di-tert-butyl-2,2’-dipyridyl (dtbpy, L1), zinc powder (Zn, >98% purity), manganese powder (Mn, 
99.99% purity), and chlorotrimethylsilane (TMSCl, ≥98% purity) were purchased from Aldrich Chemical 
Co.. 4,4’-Dimethoxy-2,2’-dipyridyl (L4), iodotrimethylsilane (TMSI, ≥95% purity), and dicobalt 
octacarbonyl (Co2(CO)8, stabilized with 1-5% hexane) were purchased from TCI Chemicals. Nickel(II) 
chloride ethylene glycol dimethyl ether complex (Ni(glyme)Cl2) was purchased from ABCR GmbH& 
Co. KG. The following known starting materials (aryl halides and nitroarenes) were prepared according 
to the literature procedures:3-14  
 
 S3   
 
 
 
 
 
 
 
 
 
 
 
 
 
 S4   
(C) General Manipulation Considerations.    
   
  All manipulations for the nickel-catalyzed reductive aminocarbonylation with nitroarenes were set up in 
a 30 mL Teflon-screw capped test tubes under an inert nitrogen (N2) atmosphere using glove-box 
techniques. The test tubes were then sealed with airtight electrical tapes and the reaction mixtures were 
stirred in a preheated oil-bath. Flash column chromatography was performed using silica gel (Silicycle, 
ultra pure grade). Preparative thin-layer chromatography (preparative TLC) was performed using 
preparative TLC plate (Merck Millipore, TLC Silica gel 60 F254, 20 x 20 cm, catalogue number: 
1.05715.0001) in a developing tank. Notably, the TLC plates used for the purification of amide products 
were washed with hexanes/triethylamine solution (volume ratio ~20:1) prior to use in order to minimize 
the product loss. The eluents for column chromatography and preparative TLC were presented as ratios 
of solvent volumes. Yields reported in the publication are of isolated materials unless otherwise noted. 
All new amide products were characterized by 1H and 13C NMR spectroscopies and high-resolution mass 
spectrometry (HRMS). All known amide products were characterized by 1H and 13C NMR spectroscopies 
and the spectra were compared with the reported data if provided.  
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Supplementary Data 
 
 
 
(A) Optimization of Reaction Conditions for Nickel-Catalyzed Reductive 
Aminocarbonylation of Aryl Iodide with Nitroarene 
 
  Iodobenzene (1a) and 1-tert-butyl-4-nitrobenzene (PhNO2, 2a) were used as the model substrates of 
aryl iodide and nitroarene, respectively. After the screening of reaction parameters, we found that the 
reductive aminocarbonylation of 1a with 2a proceeded smoothly at 120 oC in 16 h to yield the desired 
amide product, N-tert-butylphenyl benzamide (3), quantitatively in the presence of Zn reductant (2 
equiv.), TMSCl additive (10 mol %), Co2(CO)8 (0.8 equiv.), DMF solvent (0.5 M of 1a), and 
Ni(glyme)Cl2 (10 mol %) / di-tert-butyl-2,2’-dipyridyl (L1) (10 mol %) as the catalyst system (Table 
S1, entry 1). The use of other ligands (Table S1, entries 2-7), nickel catalysts (Table S1, entries 8-10), 
reductant (Mn, Table S1, entry 12), solvents (Table S1, entries 14-16), and CO surrogates (Table S1, 
entries 17 and 18) led to diminishment in yields. The variation of the loadings of Ni(glyme)Cl2 (Table 
S1, entry 11), Zn (Table S1, entry 13), Co2(CO)8 (Table S1, entry 19), and 2a (Table S1, entry 20), as 
well as the change in DMF volume (Table S1, entry 16) or reaction temperature (Table S1, entry 21), 
also resulted in drop of yields. The use of other transition metal catalysts (Fe, Co, Cu. Mn) only 
resulted in very low yields of 3 (Table S1, entries 22-25). Control experiments demonstrated that 
Ni(glyme)Cl2 catalyst and ligand L1 were essential to promote the reductive aminocarbonylation 
(Table S1, entries 26 and 27). The reaction with aniline gave lower yield of product (63%, 77%, Table 
S1, entries 28 and 29).  
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Table S1. Optimizations of Nickel-Catalyzed Reductive Aminocarbonylation of Iodobenzene with 1-
tert-Butyl-4-nitrobenzene   
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(B) Optimization of Reaction Conditions for Nickel-Catalyzed Reductive 
Aminocarbonylation of Aryl Bromide with Nitroarene  
 
 Bromobenzene (1b) and 1-tert-butyl-4-nitrobenzene (PhNO2, 2a) were used as the model substrates 
of aryl bromide and nitroarene, respectively. Initially, the optimal conditions for reductive 
aminocarbonylation of aryl iodide (Table S1, entry 1) were adopted in the reductive 
aminocarbonylation of aryl bromide. However, only a trace of desired product 3 was formed (Table 
S2, entry 1). After the screening of reaction parameters, we found that the reductive 
aminocarbonylation of 1b with 2a proceeded smoothly at 120 oC in 16 h to yield the desired amide 
product, N-tert-butylphenyl benzamide (3) in 87% yield in the presence of Mn reductant (5 equiv.), 
TMSI additive (1.5 equiv.), Co2(CO)8 (1.2 equiv.), DMF solvent (0.25 M of 1b), and Ni(glyme)Cl2 (10 
mol %) / di-methoxy -2,2’-dipyridyl (L4) (10 mol %) as the catalyst system (Table S2, entry 2). The 
use of other ligands (Table S2, entries 3 and 4), nickel catalyst (Table S2, entry 5), reductant (Zn, 
Table S2, entry 7), additives (Table S2, entries 10-11), and solvents (Table S2, entry 14) led to 
diminishment in yields. The variation of the loadings of Ni(glyme)Cl2 (Table S2, entry 6), Mn (Table 
S2, entries 8 and 9), TMSI (Entry S2, entries 12 and 13), and Co2(CO)8 (Table S2, entries 17 and 18), 
as well as the change in DMF volume (Table S1, entries 15 and 16), also resulted in drop of yields. 
Control experiments demonstrated that Ni(glyme)Cl2 catalyst and ligand L4 were essential to promote 
the reductive transmidation (Table S2, entries 19 and 20). The reaction with aniline only gave lower 
yield of product (15%, 39%, Table S2, entries 21 and 22).  
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Table S2. Optimizations of Nickel-Catalyzed Reductive Aminocarbonylation of Bromobenzene with 
1-tert-Butyl-4-nitrobenzene   
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(C) Replacing cobalt carbonyl with gaseous carbon monoxide 
 
An oven-dried 5 mL schlenk flask equipped with a Teflon-coated magnetic stir bar was sequentially charged 
with zinc powder (Zn, 2 equiv., 0.70 mmo1, 46 mg), nickel(II) chloride ethylene glycol dimethyl ether 
complex (Ni(glyme)Cl2, 10 mol %, 7.7 mg), di-tert-butyl-2,2’-dipyridyl (L1, 10 mol %, 9.4 mg) 4-(tert-
butyl)-1-iodobenzene (1 equiv., 0.35 mmol, 91.0 mg), nitrobenzene (1.5 equiv., 0.525 mmol, 64.6 mg) 
naphthalene internal standard (0.3 equiv., 0.105 mmol, 13.5 mg) dimethylformamide solvent (DMF, 0.70 
mL, 0.5 M with respect to amide), and chlorotrimethylsilane (TMSCl, 10 mol %, ~5 μL). The mixture was 
then freeze-pump-thawed through three cycles and back filled with the appropriate pressure of carbon 
monoxide. The mixture was then stirred for 16h in a preheated 120ºC oil bath. The reaction was then 
quenched with saturated ammonium chloride solution and neutralized with saturated sodium bicarbonate 
solution. The mixture was extracted with ethyl acetate and the yield estimated with GC. 
 
Pressure CO GC yield 
1.4 bar 16% 
2.4 bar 6% 
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Table S3. Reactivity of potential nitro-reduction intermediates with varying amounts of 
cobalt octacarbonyl. 
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Experimental Section  
 
 
 
Synthesis of 2-Fluoro-3-(4-nitrophenyl)pyridine (S1).  
 
An oven-dried 500 mL round-bottom flask equipped with a Teflon-coated magnetic stir bar was 
charged with 1-iodophenol (1 equiv, 10 mmol, 2.2 g), 1-bromo-2-ethoxyethane (3 equiv, 30 mmol, 4.6 
g), K2CO3 (1.5 equiv, 15 mmol, 2.1 g), NaI (50 mol %, 5 mmol, 750 mg), and DMF solvent (150 mL). 
The reaction mixture was then stirred at 120 oC in a preheated oil bath overnight. After the reaction, the 
reaction mixture was washed with water (~300 mL x 2) and ethyl acetate (EtOAc, ~200 mL). The 
organic fraction was then washed with NaOH solution (~1 M, ~150 mL) followed by saturated NaCl 
solution (~200 mL). The organic fraction was further dried with MgSO4 powder and concentrated in 
vacuo with the aid of a rotary evaporator. The residue was purified by flash chromatography with silica 
gel (without prior washing with Et3N/hexanes) using a mixture of hexanes/EtOAc (8:1) as an eluent to 
afford the title compound (2.3 g, 79%). 1H NMR (400 MHz, CDCl3): δ 7.52 (d, J = 8.8 Hz, 2 H), 6.69 
(d, J = 8.5 Hz, 2 H), 4.06 (t, J = 4.9 Hz, 2 H), 3.75 (t, J = 4.9 Hz, 2 H), 3.58 (q, J = 7.0 Hz, 2 H), 1.23 
(t, J = 7.0 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 158.8, 138.2, 117.1, 83.0, 68.8, 67.6, 66.9, 15.2. 
HRMS (ESI): Calcd for C10H13IO2 [M]: 291.9955; Found: 291.9959.  
 
 
 
Synthesis of 2-Fluoro-3-(4-nitrophenyl)pyridine (S2).  
 
In a nitrogen-filled glovebox, an oven-dried 30 mL re-sealable screw-cap test tube equipped with a 
Teflon-coated magnetic stir bar was charged with 1-iodo-4-nitrobenzene (1 equiv, 4 mmol, 996 mg), 
(2-fluoropyridin-3-yl)boronic acid (1.5 equiv, 6 mmol, 846 mg), Pd(OAc)2 (5 mol %, 45 mg), XPhos 
(10 mol%, 191 mg), K3PO4 (2 equiv, 8 mmol, 1.70 g), 1,4-dioxane solvent (10 mL), and deionized 
water (2 mL). The reaction mixture was then stirred at 100 oC in a preheated oil bath overnight. After 
the reaction, the reaction mixture was washed with water (~100 mL) and ethyl acetate (EtOAc, ~50 
mL). The aqueous fraction was further washed with EtOAc (2 x 20 mL). The combined organic 
fraction was dried with MgSO4 powder and then concentrated in vacuo with the aid of a rotary 
evaporator. The residue was purified by flash chromatography with silica gel (without prior washing 
with Et3N/hexanes) using a mixture of hexanes/EtOAc (5:1) as an eluent to afford the title compound 
(572 mg, 66%). 1H NMR (400 MHz, CD2Cl2): δ 8.34 (d, J = 8.9 Hz, 2 H), 8.32-8.30 (m, 1 H), 7.96-
7.91 (m, 1 H), 7.76 (dd, JHH = 8.8 Hz, JHF = 1.5 Hz, 2 H),7.38-7.35 (m, 1 H). 13C NMR (100 MHz, 
CD2Cl2): δ 160.3 (d, JCF = 239.6 Hz), 148.2 (d, JCF = 14.9 Hz), 147.9, 140.9 (d, JCF = 3.7 Hz), 140.8 
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(d, JCF = 5.2 Hz), 129.9 (d, JCF = 3.3 Hz), 124.1, 122.3 (d, JCF = 4.5 Hz), 121.9 (d, JCF = 27.9 Hz). 
HRMS (ESI): Calcd for C11H8FN2O2 [M+H]: 219.0564; Found: 219.0560.  
 
 
 
Amide Synthesis via Nickel-Catalyzed Reductive Aminocarbonylation of Aryl Iodide with 
Nitroarene (General Procedure A). An oven-dried 30 mL re-sealable screw-cap test tube equipped 
with a Teflon-coated magnetic stir bar was sequentially charged with zinc powder (Zn, 2 equiv., 0.70 
mmo1, 46 mg), aryl iodide (1 equiv., 0.35 mmol), nitroarene (1.5 equiv., 0.525 mmol), di-tert-butyl-
2,2’-dipyridyl (L1, 10 mol %, 9.4 mg), nickel(II) chloride ethylene glycol dimethyl ether complex 
(Ni(glyme)Cl2, 10 mol %, 7.7 mg), dicobalt octacarbonyl (Co2(CO)8, 0.8 equiv, 0.28 mmol, 101 mg), 
dimethylformaide solvent (DMF, 0.70 mL, 0.5 M with respect to amide), and chlorotrimethylsilane 
(TMSCl, 10 mol %, ~5 μL). The resulting mixture was stirred at a preheated oil bath for 16 h. After the 
reaction, the reaction mixture was cooled down to room temperature, and it was acidified with saturated 
NH4Cl solution (~5 mL) and then neutralized with saturated NaHCO3 solution (~10 mL). The crude 
product in the aqueous fraction was extracted with ethyl acetate (EtOAc, ~20 mL). The aqueous 
fraction was further washed with EtOAc (3 x ~10 mL). The combined organic fractions were 
concentrated in vacuo with the aid of a rotary evaporator. The residue was purified by preparative thin-
layer chromatography (TLC) using a solvent mixture (hexanes, EtOAc, CH2Cl2) as an eluent to afford 
the purified amide product.  
 
 
 
Amide Synthesis via Nickel-Catalyzed Reductive Aminocarbonylation of Aryl Bromide with 
Nitroarene (General Procedure B). An oven-dried 30 mL re-sealable screw-cap test tube equipped 
with a Teflon-coated magnetic stir bar was sequentially charged with manganese powder (Mn, 5 equiv., 
1.75 mmo1, 96 mg), aryl bromide (1 equiv., 0.35 mmol), nitroarene (1.5 equiv., 0.525 mmol), di-
methoxy-2,2’-dipyridyl (L4, 10 mol %, 7.6 mg), nickel(II) chloride ethylene glycol dimethyl ether 
complex (Ni(glyme)Cl2, 10 mol %, 7.7 mg), dicobalt octacarbonyl (Co2(CO)8, 1.2 equiv, 0.42 mmol, 
151 mg), dimethylformaide solvent (DMF, 1.4 mL, 0.25 M with respect to amide), and 
iodotrimethylsilane (TMSI, 1.5 equiv., 0.525 mmol, 75 μL). The resulting mixture was stirred at a 
preheated oil bath for 16 h. After the reaction, the reaction mixture was cooled down to room 
temperature, and it was acidified with saturated NH4Cl solution (~5 mL) and then neutralized with 
saturated NaHCO3 solution (~10 mL). The crude product in the aqueous fraction was extracted with 
ethyl acetate (EtOAc, ~20 mL). The aqueous fraction was further washed with EtOAc (3 x ~10 mL). 
The combined organic fractions were concentrated in vacuo with the aid of a rotary evaporator. The 
residue was purified by preparative thin-layer chromatography (TLC) using a solvent mixture (hexanes, 
EtOAc, CH2Cl2) as an eluent to afford the purified amide product.  
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N-(4-(Methylthio)phenyl)benzamide (3a).15 Following the general procedure A, the title compound 
was prepared using iodobenzene (39 uL) and 1-nitro-4-thiomethylbenzene (89 mg). The crude product 
was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title 
compound as a deep brown amorphous solid (62 mg, 73%). 1H NMR (400 MHz, CD2Cl2): δ 7.90 (s, 1 
H), 7.86 (d, J = 7.2 Hz, 2 H), 7.61-7.55 (ovrlp, 3 H), 7.50 (t, J = 7.2 Hz, 2 H), 7.28 (d, J = 8.2 Hz, 2 H), 
2.49 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 165.8, 136.2, 135.4, 134.4, 132.2, 129.2, 128.2, 127.4, 
121.2, 16.8.  
 
 
 
 
N-(3-Fluoro-4-methylphenyl)benzamide (3b). Following the general procedure A, the title compound 
was prepared using iodobenzene (39 uL) and 2-fluoro-4-nitrotoluene (82 mg). The crude product was 
purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title 
compound as a pale brown amorphous solid (53 mg, 66%). 1H NMR (400 MHz, CD2Cl2): δ 7.98 (s, 1 
H), 7.85 (d, J = 7.4 Hz, 2 H), 7.59-7.55 (ovrlp, 2 H), 7.49 (t, J = 7.2 Hz, 2 H), 7.20-7.14 (ovrlp, 2 H), 
2.25 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 165.9, 161.6 (d, 1JCF = 241.4 Hz), 137.8 (d, 3JCF = 10.7 
Hz), 135.3, 132.3, 131.8 (d, 3JCF = 6.4 Hz), 129.2, 127.4, 121.1 (d, 2JCF = 17.4 Hz), 115.8 (d, 4JCF = 3.4 
Hz), 107.8 (d, 2JCF = 27.3 Hz), 14.2 (d, 3JCF = 3.3 Hz). HRMS (ESI): Calcd for C14H13FNO [M+H]: 
230.0981; Found: 230.0984.  
 
 
 
  
N-(3-Chloro-4-methoxyphenyl)benzamide (3c). Following the general procedure A, the title 
compound was prepared using iodobenzene (39 uL) and 2-chloro-4-nitroanisole (98 mg). The crude 
product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford 
the title compound as a brown amorphous solid (69 mg, 75%). 1H NMR (400 MHz, CD2Cl2): δ 8.00 (s, 
1 H), 7.84 (d, J = 7.0 Hz, 2 H), 7.73 (s, 1 H), 7.55 (d, J = 6.9 Hz, 1 H), 7.50-7.44 (ovrlp, 3 H), 6.92 (d, J 
= 8.8 Hz, 1 H), 3.88 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 166.0, 152.5, 135.1, 132.2, 132.1, 129.1, 
127.4, 123.2, 122.7, 120.6, 112.7, 56.7. HRMS (ESI): Calcd for C14H13ClNO2 [M+H]: 262.0645; 
Found: 262.0641.  
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N-(3-Bromo-4-methylphenyl)benzamide (3d). Following the general procedure A, the title compound 
was prepared using iodobenzene (39 uL) and 2-bromo-4-nitrotoluene (113 mg). The crude product was 
purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title 
compound as a deep brown amorphous solid (68 mg, 67%). 1H NMR (400 MHz, CD2Cl2): δ 8.15 (s, 1 
H), 7.93 (d, J = 1.5 Hz, 1 H), 7.84 (d, J = 7.5 Hz, 2 H), 7.54 (d, J = 1.8 Hz, 1 H), 7.47-7.44 (ovrlp, 3 H), 
7.20 (d, J = 8.2 Hz, 1 H), 2.37 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 166.1, 137.4, 135.1, 134.3, 
132.3, 131.1, 129.1, 127.4, 125.0, 124.4, 119.8, 22.4. HRMS (ESI): Calcd for C14H13BrNO [M+H]: 
290.0189; Found: 290.0181.  
 
 
 
 
N-(4-(2-Fluoropyridin-3-yl)phenyl)benzamide (3e). Following the general procedure A, the title 
compound was prepared using iodobenzene (39 uL) and 2-fluoro-3-(4-nitrophenyl)pyridine (114 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (65:30:5) as an 
eluent to afford the title compound as a brown amorphous solid (68 mg, 66%). 1H NMR (400 MHz, 
CD2Cl2): δ 8.17 (s, 1 H), 8.01 (s, 1 H), 7.94-7.87 (ovrlp, 3 H), 7.79 (d, J = 7.6 Hz, 2 H), 7.62-7.58 
(ovrlp, 3 H), 7.53 (t, J = 6.4 Hz, 2 H), 7.31 (t, J = 6.5 Hz, 1 H). 13C NMR (100 MHz, DMSO-d6): δ 
165.7, 159.6 (d, JCF = 235.6 Hz), 146.0 (d, JCF = 14.8 Hz), 141.0 (d, JCF = 4.2 Hz), 139.5, 134.8, 131.7, 
129.0 (d, JCF = 3.0 Hz), 128.4, 127.7, 122.60 (d, JCF = 27.8 Hz), 122.65 (d, JCF = 4.1 Hz), 120.4. 
HRMS (ESI): Calcd for C18H14FN2O [M+H]: 293.1090; Found: 293.1104.  
 
 
 
 
N-(4-(1H-Pyrrol-1-yl)phenyl)benzamide (3f). Following the general procedure A, the title compound 
was prepared using iodobenzene (39 uL) and 1-(4-nitrophenyl)-1H-pyrrole (99 mg). The crude product 
was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title 
compound as a reddish-brown amorphous solid (39 mg, 42%). 1H NMR (400 MHz, DMSO-d6): δ 
10.34 (s, 1 H), 7.98 (d, J = 6.7 Hz, 2 H), 7.88 (d, J = 8.0 Hz, 2 H), 7.62-7.51 (ovrlp, 5 H), 7.34 (s, 2 H), 
6.26 (s, 2 H). 13C NMR (100 MHz, DMSO-d6): δ 165.4, 136.5, 135.7, 134.8, 131.6, 128.4, 127.6, 
121.3, 119.5, 118.8, 110.2. HRMS (ESI): Calcd for C17H15N2O [M+H]: 263.1184; Found: 263.1190. 
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N-(1H-Indol-6-yl)benzamide (3g). Following the general procedure A, the title compound was 
prepared using iodobenzene (39 uL) and 6-nitro-1H-indole (85 mg), Ni(glyme)Cl2 (15 mol %, 11.6 
mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF (1.4 mL). The crude product was 
purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title 
compound as a brown amorphous solid (39 mg, 47%). 1H NMR (400 MHz, DMSO-d6): δ 11.06 (s, 1 
H), 10.19 (s, 1 H), 8.09 (s, 1 H), 7.98 (d, J = 7.0 Hz, 2 H), 7.60-7.51 (ovrlp, 3 H), 7.48 (d, J = 8.6 Hz, 1 
H), 7.31-7.28 (ovrlp, 2 H), 6.38 (s, 1 H). 13C NMR (400 MHz, DMSO-d6): δ 165.2, 135.8, 135.4, 
133.2, 131.2, 128.3, 127.6, 125.1, 124.2, 119.6, 113.4, 103.3, 100.9. HRMS (ESI): Calcd for 
C15H13N2O [M+H]: 237.1028; Found: 237.1029. 
 
 
 
 
N-(3-Cyano-4-methylphenyl)-4-methoxybenzamide (3h). Following the general procedure A, the 
title compound was prepared using 4-iodoanisole (82 mg), 2-cyano-4-nitrotoluene (85 mg), and 
Co2(CO)8 (1 equiv, 120 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (65:30:5) as an eluent to afford the title compound as brown amorphous solid 
(51 mg, 55%). 1H NMR (400 MHz, CDCl3): δ 8.03 (s, 1 H), 7.92 (d, J = 1.6 Hz, 1 H), 7.83 (d, J = 8.7 
Hz, 2 H), 7.73 (dd, J = 8.3 Hz, J = 1.6 Hz, 1 H), 7.27 (d, J = 7.0 Hz, 1 H), 6.95 (d, J = 8.7 Hz, 2 H), 
3.86 (s, 3 H), 2.50 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 165.5, 162.9, 137.7, 136.6, 131.0, 129.2, 
126.4, 124.8, 123.8, 118.0, 114.2, 113.2, 55.6, 20.0. HRMS (ESI): Calcd for C16H15N2O2 [M+H]: 
267.1133; Found: 267.1142. 
 
 
 
 
N-(2,3-Dihydro-1H-inden-4-yl)-4-methoxybenzamide (3i).16 Following the general procedure A, the 
title compound was prepared using 4-iodoanisole (82 mg) and 4-nitro-2,3-dihydro-1H-indene (86 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an 
eluent to afford the title compound as a pale brown amorphous solid (85 mg, 91%). 1H NMR (400 
MHz, CDCl3): δ 7.85-7.81 (ovrlp, 3 H), 7.64 (s, 1 H), 7.18 (t, J = 7.6 Hz, 1 H), 7.04 (d, J = 7.2 Hz, 1 
H), 6.96 (d, J = 8.4 Hz, 2 H), 3.85 (s, 3 H), 2.96 (t, J = 7.2 Hz, 2 H), 2.87 (t, J = 7.2 Hz, 2 H), 2.12 (qu, 
J = Hz, 2 H). 13C NMR (100 MHz, CDCl3): δ 165.1, 162.5, 145.4, 134.4, 134.3, 129.0, 127.4, 127.3, 
120.9, 119.0, 114.1, 55.6, 33.3, 30.2, 24.9.  
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N-(2,4-Dimethylphenyl)-4-methoxybenzamide (3j). Following the general procedure A, the title 
compound was prepared using 4-iodoanisole (82 mg) and 2,4-dimethyl-nitrobenzene (79 mg). The 
crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to 
afford the title compound as an off-white amorphous solid (76 mg, 85%). 1H NMR (400 MHz, 
CD2Cl2): δ 7.84 (d, J = 8.8 Hz, 2 H), 7.66-7.60 (ovrlp, 2 H), 7.06 (s, 1 H), 7.04 (d, J = 8.2 Hz, 1 H), 
6.98 (d, J = 8.8 Hz, 2 H), 3.87 (s, 3 H), 2.32 (s, 3 H), 2.27 (s, 3 H). 13C NMR (100 MHz, CD2Cl2): δ 
165.4, 162.8, 135.5, 133.9, 131.5, 130.8, 129.3, 127.6, 127.5, 124.1, 114.2, 55.9, 21.0, 18.0. HRMS 
(ESI): Calcd for C16H18NO2 [M+H]: 256.1338; Found: 256.1353. 
 
 
 
 
4-Methoxy-N-(6-methoxypyridin-3-yl)benzamide (3k). Following the general procedure A, the title 
compound was prepared using 4-iodoanisole (82 mg), 2-methoxy-5-nitropyridine (1.5 equiv., 81 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF 
(1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (65:30:5) 
as an eluent to afford the title compound as a brown amorphous solid (47 mg, 52%). 1H NMR (400 
MHz, CDCl3): δ 8.25 (s, 1 H), 8.11 (s, 1 H), 7.97 (d, J = 7.8 Hz, 1 H), 7.83 (d, J = 7.8 Hz, 2 H), 6.91 (d, 
J = 7.7 Hz, 2 H), 6.71 (d, J = 8.4 Hz, 1 H), 3.91 (s, 3 H), 3.84 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 
165.8, 162.7, 161.2, 139.2, 133.0, 129.2, 128.9, 126.6, 114.1, 110.7, 55.6, 53.7. HRMS (ESI): Calcd 
for C14H15N2O3 [M+H]: 259.1083; Found: 259.1087.  
 
 
 
 
4-Methoxy-N-(2-methylbenzo[d]thiazol-6-yl)benzamide (3l). Following the general procedure A, the 
title compound was prepared using 4-iodoanisole (82 mg) and 2-methyl-6-nitrobenzo[d]thiazole (102 
mg). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an 
eluent to afford the title compound as a reddish-brown amorphous solid (66 mg, 63%). 1H NMR (400 
MHz, DMSO-d6): δ 10.28 (s, 1 H), 8.53 (d, J = 1.1 Hz, 1 H), 7.98 (d, J = 8.7 Hz, 2 H), 7.86 (d, J = 8.7 
Hz, 1 H), 7.74 (dd, J = 8.7 Hz, J = 1.5 Hz, 1 H), 7.08 (d, J = 8.6 Hz, 2 H), 3.85 (s, 3 H), 2.77 (s, 3 H). 
13C NMR (100 MHz, DMSO-d6): δ 165.5, 165.0, 162.0, 149.2, 136.4, 135.6, 129.6, 126.8, 121.6, 
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119.6, 113.6, 112.6, 55.4, 19.7. HRMS (ESI): Calcd for C16H15N2O2S [M+H]: 299.0854; Found: 
299.0851. 
 
 
 
 
4-Methoxy-N-(2-oxo-2H-chromen-6-yl)benzamide (3m). Following the general procedure A, the title 
compound was prepared using 4-iodoanisole (82 mg), 6-nitro-2H-chromen-2-one (1.5 equiv., 100 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF 
(1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) 
as an eluent to afford the title compound as a pale brown amorphous solid (45 mg, 43%). 1H NMR 
(400 MHz, DMSO-d6): δ 10.30 (s, 1 H), 8.21 (s, 1 H), 8.09-7.87 (ovrlp, 4 H), 7.40 (d, J = 5.9 Hz, 1 H), 
7.07 (s, 2 H), 6.49 (d, J = 7.7 Hz, 1 H), 3.84 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 164.9, 162.0, 
160.0, 149.5, 144.4, 135.7, 129.6, 126.5, 124.5, 119.0, 118.6, 116.4, 113.6, 55.4. HRMS (ESI): Calcd 
for C17H14NO4 [M+H]: 296.0923; Found: 296.0922. 
 
 
 
 
(E)-4-(2-ethoxyethoxy)-N-(4-styrylphenyl)benzamide (3n). Following the general procedure A, the 
title compound was prepared using 1-(2-ethoxyethoxy)-4-iodobenzene (102 mg), (E)-1-nitro-4-
styrylbenzene (118 mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 
equiv, 120 mg), and DMF (1.4 mL). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title compound as a brown amorphous solid 
(84 mg, 62%). 1H NMR (400 MHz, DMSO-d6): δ 10.17 (s, 1 H), 7.97 (d, J = 8.5 Hz, 2 H), 7.82 (d, J = 
8.3 Hz, 2 H), 7.62-7.54 (ovrlp, 4 H), 7.37 (t, J = 7.4 Hz, 2 H), 7.28-7.18 (ovrlp, 3 H), 7.08 (d, J = 8.5 
Hz, 2 H), 4.17 (t, J = 4.2 Hz, 2 H), 3.72 (t, J = 4.0 Hz, 2 H), 3.51 (q, J = 6.9 Hz, 2 H), 1.13 (t, J = 7.0 
Hz, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 164.8, 161.2, 138.9, 137.2, 132.1, 129.6, 128.6, 128.0, 
127.3, 127.0, 126.9, 126.7, 126.2, 120.3, 114.0, 68.2, 67.4, 65.7, 15.1. HRMS (ESI): Calcd for 
C25H26NO3 [M+H]: 388.1913; Found: 388.1911. 
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4-(4-(tert-Butyl)benzamido)phenyl pivalate (3o). Following the general procedure A, the title 
compound was prepared using 1-tert-butyl-4-iodobenzene (91 mg), 4-nitrophenyl pivalate (117 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF 
(1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) 
as an eluent to afford the title compound as a white amorphous solid (74 mg, 60%). 1H NMR (400 
MHz, CDCl3): δ 8.07 (s, 1 H), 7.79 (d, J = 8.4 Hz, 2 H), 7.61 (d, J = 8.8 Hz, 2 H), 7.45 (d, J = 8.4 Hz, 2 
H), 6.99 (d, J = 8.8 Hz, 2 H), 1.35 (s, 9 H), 1.34 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 177.5, 165.9, 
155.4, 147.4, 135.8, 132.0, 127.1, 125.7, 121.9, 121.3, 39.2, 35.1, 31.3, 27.3. HRMS (ESI): Calcd for 
C22H28NO3 [M+H]: 354.2069; Found: 354.2079. 
 
 
 
 
N-(4-(9H-Carbazol-9-yl)phenyl)-4-methylbenzamide (3p).16 Following the general procedure A, the 
title compound was prepared using 4-iodotoluene (76 mg), 9-(4-nitrophenyl)-9H-carbazole (151 mg), 
and DMF (1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 
(85:10:5) as an eluent to afford the title compound as a brown amorphous solid (82 mg, 62%). 1H 
NMR (400 MHz, CDCl3): δ 8.14 (d, J = 7.8 Hz, 2 H), 7.98 (s, 1 H), 7.88 (d, J = 8.8 Hz, 2 H), 7.83 (d, J 
= 8.2 Hz, 2 H), 7.55 (d, J = 8.7 Hz, 2 H), 7.43-7.38 (ovrlp, 4 H), 7.32 (d, J = 8.2 Hz, 2 H), 7.30-7.26 
(m, 2 H), 2.45 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 166.1, 142.8, 141.1, 137.4, 133.8, 131.9, 129.6, 
127.9, 127.3, 126.1, 123.4, 121.7, 120.4, 120.0, 109.8, 21.6. 
 
 
 
 
N-(4-(1H-Pyrazol-1-yl)phenyl)-2-methylbenzamide (3q). Following the general procedure A, the 
title compound was prepared using 2-iodotoluene (76 mg), 1-(4-nitrophenyl)-1H-pyrazole (99 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), and Co2(CO)8 (1 equiv, 120 mg). The 
crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to 
afford the title compound as a brown amorphous solid (41 mg, 42%). 1H NMR (400 MHz, CDCl3): δ 
7.89 (s, 1 H), 7.77 (s, 1 H), 7.73-7.60 (ovrlp, 5 H), 7.47 (d, J = 6.6 Hz, 1 H), 7.36 (t, J = 6.7 Hz, 1 H), 
7.30-7.21 (ovrlp, 2 H), 6.46 (s, 1 H), 2.50 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 168.2, 141.1, 136.8, 
136.64, 136.57, 136.2, 131.4, 130.5, 126.9, 126.8, 126.0, 120.9, 120.0, 107.7, 20.0. HRMS (ESI): 
Calcd for C17H16N3O [M+H]: 278.1293; Found: 278.1293. 
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N-(4-(tert-Butyl)phenyl)-4-chlorobenzamide (3r). Following the general procedure A, the title 
compound was prepared using 1-chloro-4-iodobenzene (84 mg) and 1-(tert-butyl)-4-nitrobenzene (95 
mg). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an 
eluent to afford the title compound as a white amorphous solid (55 mg, 55%). 1H NMR (400 MHz, 
CDCl3): δ 7.88 (s, 1 H), 7.78 (d, J = 8.4 Hz, 2 H), 7.53 (d, J = 8.5 Hz, 2 H), 7.41 (d, J = 8.4 Hz, 2 H), 
7.37 (d, J = 8.6 Hz, 2 H), 1.32 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 164.8, 148.0, 138.1, 135.2, 
133.6, 129.1, 128.6, 126.1, 120.3, 34.6, 31.5. HRMS (ESI): Calcd for C17H19ClNO [M+H]: 288.1155; 
Found: 288.1154. 
 
 
 
 
N-(4-(tert-Butyl)phenyl)-4-fluorobenzamide (3s).16 Following the general procedure A, the title 
compound was prepared using 1-fluoro-4-iodobenzene (78 mg) and 1-(tert-butyl)-4-nitrobenzene (94 
mg). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an 
eluent to afford the title compound as a brown amorphous solid (56 mg, 60%). 1H NMR (400 MHz, 
CDCl3): δ 7.95 (s, 1 H), 7.85 (dd, 3JHH = 8.1 Hz, 4JCF = 5.6 Hz, 2 H), 7.53 (d, J = 8.4 Hz, 2 H), 7.36 (d, 
J = 8.4 Hz, 2 H), 7.10 (dd, 3JHH = 8.1 Hz, 3JCF = 8.1 Hz, 2 H), 1.32 (s, 9 H). 13C NMR (100 MHz, 
CDCl3): δ 164.93 (d, 1JCF = 250.9 Hz), 164.91, 147.9, 135.3, 131.3 (d, 4JCF = 3.1 Hz), 129.6 (d, 3JCF = 
8.9 Hz), 126.0, 120.4, 115.9 (d, 2JCF = 21.8 Hz), 34.6, 31.5.  
 
 
 
 
N-(4-(Phenylthio)phenyl)-4-(trifluoromethoxy)benzamide (3t). Following the general procedure A, 
the title compound was prepared using 1-iodo-4-(trifluoromethoxy)benzene (101 mg) and (4-
nitrophenyl)(phenyl)sulfane (121 mg) and DMF (1.4 mL). The crude product was purified by 
preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a 
brown amorphous solid (56 mg, 41%). 1H NMR (400 MHz, CDCl3): δ 7.98 (s, 1 H), 7.88 (d, J = 8.2 
Hz, 2 H), 7.58 (d, J = 8.0 Hz, 2 H), 7.37 (d, J = 8.0 Hz, 2 H), 7.33-7.19 (ovrlp, 7 H). 13C NMR (100 
MHz, CD2Cl2): δ 164.7, 152.1, 137.9, 137.0, 133.8, 133.2, 131.2, 130.6, 129.6, 129.5, 127.3, 121.5, 
121.3, 120.8 (1, 1JCF = 256.7 Hz). HRMS (ESI): Calcd for C20H14F3NO2S [M+H]: 390.0775; Found: 
390.0787.  
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N-(4-(tert-Butyl)phenyl)-4-(trifluoromethyl)benzamide (3u).16 Following the general procedure A, 
the title compound was prepared using 4-iodobenzotrifluoride (95 mg) and 1-(tert-butyl)-4-
nitrobenzene (94 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a brown amorphous solid 
(62 mg, 55%). 1H NMR (400 MHz, CDCl3): δ 8.69 (s, 1 H), 7.85 (d, J = 7.9 Hz, 2 H), 7.55-7.52 (ovrlp, 
4 H), 7.31 (d, J = 8.4 Hz, 2 H), 1.30 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 165.2, 148.2, 138.3, 
135.1, 133.3 (q, 2JCF = 32.5 Hz), 127.8, 125.9, 125.6 (q, 3JCF = 3.7 Hz), 123.7 (q, 1JCF = 270.9 Hz), 
120.8, 34.5, 31.4.  
 
 
 
 
N-(4-(tert-Butyl)phenyl)-4-cyanobenzamide (3v). Following the general procedure A, the title 
compound was prepared using 4-iodobenzonitrile (80 mg) and 1-(tert-butyl)-4-nitrobenzene (95 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a pale brown amorphous solid (56 mg, 57%). 1H NMR (400 
MHz, CDCl3): δ 7.98-7.94 (ovrlp, 3 H), 7.75 (d, J = 7.9 Hz, 2 H), 7.54 (d, J = 7.7 Hz, 2 H), 7.39 (d, J = 
8.2 Hz, 2 H), 1.32 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 164.0, 148.5, 139.1, 134.8, 132.7, 127.9, 
126.2, 120.4, 118.1, 115.4, 34.6, 31.5. HRMS (ESI): Calcd for C18H19N2O [M+H]: 279.1497; Found: 
279.1499. 
 
 
 
 
4-(3-Methoxybenzamido)phenyl 4-methylbenzenesulfonate (3w). Following the general procedure 
A, the title compound was prepared using 3-iodoanisole (82 mg) and 4-nitrophenyl 4-
methylbenzenesulfonate (154 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a brown amorphous n 
solid (61 mg, 44%). 1H NMR (400 MHz, CDCl3): δ 7.82 (s, 1 H), 7.71 (d, J = 8.2 Hz, 2 H), 7.57 (d, J = 
9.0 Hz, 2 H), 7.42-7.36 (ovrlp, 3 H), 7.31 (d, J = 8.1 Hz, 2 H), 7.09 (d, J = 8.6 Hz, 1 H), 6.97 (d, J = 8.9 
Hz, 2 H), 3.87 (s, 3 H), 2.45 (s, 3 H). 13C NMR (400 MHz, CDCl3): δ 165.6, 160.2, 145.9, 145.6, 
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136.9, 136.2, 132.3, 130.0, 129.9, 128.7, 123.2, 121.1, 118.7, 118.3, 112.7, 55.7, 21.9. HRMS (ESI): 
Calcd for C21H20NO5S [M+H]: 398.1062; Found: 398.1055. 
 
 
 
 
N-(4-(2-Ethyloxazol-5-yl)phenyl)-3-methoxybenzamide (3x). Following the general procedure A, the 
title compound was prepared using 3-iodoanisole (82 mg) and 2-ethyl-5-(4-nitrophenyl)oxazole (115 
mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and 
DMF (1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 
(75:20:5) as an eluent to afford the title compound as a pale brown amorphous solid (51 mg, 46%). 1H 
NMR (400 MHz, DMSO-d6): δ 10.35 (s, 1 H), 7.89 (d, J = 8.5 Hz, 2 H), 7.66 (d, J = 8.5 Hz, 2 H), 
7.61-7.39 (ovrlp, 4 H), 7.17 (dd, J = 7.8 Hz, J = 1.4 Hz, 1 H), 3.84 (s, 3 H), 2.81 (q, J = 7.5 Hz, 2 H), 
1.29 (t, J = 7.5 Hz, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 165.3, 164.4, 159.2, 150.0, 139.0, 136.2, 
129.6, 124.1, 123.1, 121.5, 120.6, 119.9, 117.4, 112.9, 55.3, 21.0, 11.0. HRMS (ESI): Calcd for 
C19H19N2O3 [M+H]: 323.1396; Found: 323.1395. 
 
 
 
 
N-(4-(1,3-Dioxolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide (3y). Following the general 
procedure A, the title compound was prepared using 3-iodobenzotrifluoride (95 mg) and 2-(4-
nitrophenyl)-1,3-dioxolane (1.5 equiv., 103 mg). The crude product was purified by preparative TLC 
using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a brown 
amorphous solid (63 mg, 54%). 1H NMR (400 MHz, DMSO-d6): δ 10.54 (s, 1 H), 8.37-8.25 (ovrlp, 2 
H), 7.96 (d, J = 1.7 Hz, 1 H), 7.86-7.74 (ovrlp, 3 H), 7.44 (d, J = 7.8 Hz, 2 H), 5.70 (s, 1 H), 4.11-4.04 
(m, 2 H), 4.02-3.89 (m, 2 H). 13C NMR (100 MHz, DMSO-d6): δ 164.0, 139.5, 135.6, 133.6, 131.8, 
129.7, 129.1 (q, 2JCF = 31.9 Hz), 128.1 (q, 3JCF = 2.6 Hz), 127.0, 124.2 (q, 3JCF = 3.6 Hz), 123.9 (q, 1JCF 
= 271.1 Hz), 120.1, 102.6, 64.7. HRMS (ESI): Calcd for C17H15F3NO3 [M+H]: 388.1104; Found: 
338.0999. 
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N-(4-(2-Methyl-1,3-dioxolan-2-yl)phenyl)-3-(trifluoromethyl)benzamide (3z). Following the 
general procedure A, the title compound was prepared using 3-iodobenzotrifluoride (95 mg) and 2-
methyl-2-(4-nitrophenyl)-1,3-dioxolane (110 mg). The crude product was purified by preparative TLC 
using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a pale-brown 
amorphous solid (98 mg, 80%). 1H NMR (400 MHz, DMSO-d6): δ 10.49 (s, 1 H), 8.35-8.21 (ovrlp, 2 
H), 7.96 (d, J = 4.8 Hz, 1 H), 7.83-7.69 (ovrlp, 3 H), 7.42 (d, J = 5.7 Hz, 2 H), 4.05-3.91 (m, 2 H), 3.77-
3.65 (m, 2 H), 1.56 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 164.0, 138.8, 138.3, 135.7, 131.8, 
129.7, 129.2 (q, 2JCF = 32.1 Hz), 128.1 (q, 3JCF = 2.4 Hz), 125.4, 124.2 (q, 3JCF = 3.2 Hz), 124.0 (q, 1JCF 
= 271.3 Hz), 120.2, 108.0, 64.0, 27.2. HRMS (ESI): Calcd for C18H17F3NO3 [M+H]: 352.1161; Found: 
352.1154. 
 
 
 
 
N-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)phenyl)-3-methylbenzamide (3aa). Following the 
general procedure A, the title compound was prepared using 3-iodotoluene (76 mg) and tert-
butyldimethyl(4-nitrophenethoxy)silane (139 mg). The crude product was purified by preparative TLC 
using hexanes/EtOAc/CH2Cl2 (90:5:5) as an eluent to afford the title compound as a viscous brown 
solid (64 mg, 50%). 1H NMR (400 MHz, CDCl3): δ 7.98 (s, 1 H), 7.66 (s, 1 H), 7.62 (t, J = 3.2 Hz, 1 
H), 7.55 (d, J = 8.0 Hz, 2 H), 7.34-7.28 (ovrlp, 2 H), 7.18 (d, J = 8.1 Hz, 2 H), 3.79 (t, J = 6.9 Hz, 2 H), 
2.80 (t, J = 6.9 Hz, 2 H), 2.38 (s, 3 H), 0.88 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 166.0, 138.7, 
136.3, 135.5, 135.1, 132.5, 129.8, 128.6, 127.9, 124.1, 120.3, 64.6, 39.2, 26.1, 21.5, 18.4. -5.2. HRMS 
(ESI): Calcd for C22H32NO2Si [M+H]: 370.2202; Found: 370.2199. 
 
 
 
 
N-(4-(Dimethylamino)phenyl)-3-methylbenzamide (3bb). Following the general procedure A, the 
title compound was prepared using 3-iodotoluene (76 mg) and N,N-dimethyl-4-nitroaniline (87 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a pale brown amorphous solid (65 mg, 73%). 1H NMR (400 
MHz, CDCl3): δ 7.93 (s, 1 H), 7.65 (s, 1 H), 7.60 (s, 1 H), 7.47 (d, J = 8.3 Hz, 2 H), 7.31-7.25 (ovrlp, 2 
H), 6.69 (d, J = 8.6 Hz, 2 H), 2.90 (s, 6 H), 2.36 (s, 3 H). 13C NMR (100 MHz, CDCl3): δ 165.9, 148.1, 
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138.5, 135.3, 132.2, 128.5, 128.0, 127.9, 124.0, 122.2, 113.1, 41.0, 21.4. HRMS (ESI): Calcd for 
C16H19N2O [M+H]: 255.1497; Found: 255.1501. 
 
 
 
 
3-Methyl-N-(2-phenylbenzo[d]oxazol-5-yl)benzamide (3cc). Following the general procedure A, the 
title compound was prepared using 3-iodotoluene (76 mg), 5-nitro-2-phenylbenzo[d]oxazole (126 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF 
(1.4 mL). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) 
as an eluent to afford the title compound as a off-white amorphous solid (93 mg, 81%). 1H NMR (400 
MHz, DMSO-d6): δ 10.39 (s, 1 H), 8.30 (s, 1 H), 8.24-8.17 (ovrlp, 2 H), 7.82-7.75 (ovrlp, 4 H), 7.64-
7.59 (ovrlp, 3 H), 7.45-7.39 (ovlp, 2 H), 2.41 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 165.7, 162.9, 
146.6, 141.6, 137.7, 136.4, 134.9, 132.2, 131.9, 129.3, 128.3, 128.1, 127.2, 126.4, 124.8, 118.8, 111.2, 
110.5, 21.0. HRMS (ESI): Calcd for C21H17N2O2 [M+H]: 329.1290; Found: 329.1291. 
 
 
 
N-(4-(tert-Butyl)phenyl)picolinamide (3dd). Following the general procedure A, the title compound 
was prepared using 2-iodopyridine (72 mg) and 1-(tert-butyl)-4-nitrobenzene (95 mg), Ni(glyme)Cl2 
(15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), and Co2(CO)8 (1 equiv, 120 mg). The crude product 
was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title 
compound as an off-white amorphous solid (46 mg, 51%). 1H NMR (400 MHz, CDCl3): δ 9.97 (s, 1 
H), 8.61 (d, J = 3.7 Hz, 1 H), 8.30 (d, J = 7.6 Hz, 1 H), 7.90 (t, J = 7.5 Hz, 1 H), 7.70 (d, J = 8.4 Hz, 2 
H), 7.47 (dd, J = 6.4 Hz, J = 5.2 Hz, 1 H), 7.41 (d, J = 8.4 Hz, 2 H), 1.33 (s, 9 H). 13C NMR (100 MHz, 
CDCl3): δ 162.0, 150.1, 148.1, 147.4, 137.8, 135.3, 126.5, 126.0, 122.5, 119.6, 34.6, 31.5. HRMS 
(ESI): Calcd for C16H19N2O [M+H]: 255.1497; Found: 255.1503. 
 
 
 
 
N-(4-(tert-Butyl)phenyl)-1-methyl-1H-pyrazole-4-carboxamide (3ee). Following the general 
procedure A, the title compound was prepared using 4-iodo-1-methyl-1H-pyrazole (73 mg) and 1-(tert-
butyl)-4-nitrobenzene (1.5 equiv., 88 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (65:30:5) as an eluent to afford the title compound as a brown amorphous solid 
(59 mg, 66%). 1H NMR (400 MHz, CDCl3): δ 8.29 (s, 1 H), 8.03-7.86 (ovrlp, 2 H), 7.52 (d, J = 7.2 Hz, 
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2 H), 7.30 (d, J = 7.5 Hz, 2 H), 3.78 (s, 3 H), 1.28 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 161.4 (br), 
147.4, 138.9 (br), 135.4, 132.8 (br), 125.8, 120.5, 119.5 (br), 39.3, 34.4, 31.4. HRMS (ESI): Calcd for 
C15H20N3O [M+H]: 258.1606; Found: 258.1607. 
 
 
 
N
H
O
t-Bu  
4-(tert-butyl)-N-phenylbenzamide (3ff). The title compound was prepared using 4-(tert-butyl)-1-
iodobenzene (92.8 mg) and nitrobenzene (69.8 mg). The crude product was purified by preparative 
TLC using hexanes/EtOAc/CH2Cl2 (170/20/10) as an eluent to afford the title compound as an off-
white amorphous solid (53 mg, 59%). 1H NMR (400 MHz, CDCl3): δ 7.93 (s, 1H), 7.81 (d, J = 8.4 Hz, 
2H), 7.65 (d, J = 7.2 Hz, 1H), 7.48 (d, J = 8.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.14 (t, J = 7.4 Hz, 1H), 
1.35 (s, 9H). 13C NMR (100 MHz, CDCl3): δ 165.72, 155.41, 138.09, 132.11, 129.06, 126.91, 125.71, 
124.41, 120.20, 77.37, 77.05, 76.73, 35.00, 31.18. HRMS (ESI): Calcd for C17H20NO [M+H]: 
254.1545; Found: 254.1541 
 
 
 
N
H
O
t-Bu
Cl
 
4-(tert-butyl)-N-(4-chlorophenyl)benzamide (3gg). The title compound was prepared using 4-(tert-
butyl)-1-iodobenzene (97.1 mg) and 1-chloro-4-nitrobenzene (85.4 mg). The crude product was 
purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (170/20/10) as an eluent to afford the title 
compound as a light-yellow amorphous solid (47 mg, 44%). 1H NMR (400 MHz, DMSO-d6) δ 10.29 (s, 
1H), 7.88 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.9 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.8 Hz, 2H), 
1.32 (s, 9H). 13C NMR (101 MHz, DMSO) δ 166.05, 155.04, 138.72, 132.47, 128.96, 128.01, 127.56, 
125.65, 122.20, 40.63, 40.42, 40.21, 40.00, 39.79, 39.58, 39.37, 35.17, 31.40. HRMS (ESI): Calcd for 
C17H19ClNO [M+H]: 288.1155; Found: 288.1147 
 
 
 
 
4-Methoxy-N-(quinolin-6-yl)benzamide (4a). Following the general procedure B, the title compound 
was prepared using 4-bromoanisole (66 mg), 6-nitroquinoline (91 mg), Ni(glyme)Cl2 (15 mol %, 11.6 
mg), and L4 (15 mol %, 14.1 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (65:30:5) as an eluent to afford the title compound as a brown amorphous solid 
(70 mg, 71%). 1H NMR (400 MHz, DMSO-d6): δ 10.43 (s, 1 H), 8.81 (dd, J = 3.9 Hz, J = 1.2 Hz, 1 H), 
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8.54 (d, J = 2.1 Hz, 1 H), 8.32 (dd, J = 8.4 Hz, J = 0.8 Hz, 1 H), 8.09-8.00 (ovrlp, 4 H), 7.50 (dd, J = 
8.3 Hz, J = 4.2 Hz, 1 H), 7.09 (d, J = 8.8 Hz, 2 H), 3.85 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 
165.3, 162.1, 148.9, 144.6, 137.4, 135.7, 129.7, 129.1, 128.3, 126.7, 124.4, 121.7, 116.1, 113.7, 55.4. 
HRMS (ESI): Calcd for C17H15N2O2 [M+H]: 279.1133; Found: 279.1142. 
 
 
 
 
4-Fluoro-N-(4-(phenylamino)phenyl)benzamide (4b). Following the general procedure B, the title 
compound was prepared using 1-fluoro-4-nitrobenzene (61 mg) and 4-nitro-N-phenylaniline (112 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a brown amorphous solid (78 mg, 73%). 1H NMR (400 MHz, 
DMSO-d6): δ 10.12 (s, 1 H), 8.09 (s, 1 H), 8.03 (dd, 3JHH = 8.6 Hz, 4JHF = 5.7 Hz, 2 H), 7.63 (d, J = 8.0 
Hz, 2 H), 7.35 (dd, 3JHH = 8.3 Hz, 3JHF = 8.3 Hz, 2 H), 7.21 (t, J = 7.0 Hz, 2 H), 7.09-7.03 (ovrlp, 4 H), 
6.78 (t, J = 6.7 Hz, 1 H). 13C NMR (100 MHz. CDCl3): δ 163.93 (d, 1JCF = 246.6 Hz), 163.90, 143.9, 
139.4, 131.7, 131.5 (d, 4JCF = 2.2 Hz), 130.2 (d, 3JCF = 8.7 Hz), 129.1, 121.8, 119.1, 117.4, 116.0, 115.2 
(d, 2JCF = 21.7). HRMS (ESI): Calcd for C19H16FN2O [M+H]: 307.1247; Found: 307.1247. 
 
 
 
 
4-Benzoyl-N-(4-methoxyphenyl)benzamide (4c). Following the general procedure B, the title 
compound was prepared using (4-bromophenyl)(phenyl)methanone (91 mg) and 4-nitroanisole (80 
mg). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a pale brown amorphous solid (55 mg, 47%). 1H NMR (400 
MHz, CDCl3): δ 7.97 (d, J = 7.8 Hz, 2 H), 7.90-7.86 (ovrlp, 3 H), 7.81 (d, J = 7.4 Hz, 2 H), 7.63 (t = J 
= 8.6 Hz, 1 H), 7.57 (d, J = 8.4 Hz, 2 H), 7.51 (t, J = 7.7 Hz, 2 H), 6.93 (d, J = 8.6 Hz, 2 H), 3.82 (s, 3 
H). 13C NMR (100 MHz, CDCl3): δ 196.0, 164.9, 157.0, 140.4, 138.4, 137.1, 133.1, 130.8, 130.4, 
130.2, 128.6, 127.1, 122.3, 114.5, 55.7.  HRMS (ESI): Calcd for C21H18NO3 [M+H]: 332.1287; Found: 
322.1286. 
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N1,N1-Diethyl-N4-(p-tolyl)terephthalamide (4d). Following the general procedure B, the title 
compound was prepared using 4-bromo-N,N-diethylbenzamide (90 mg) and 4-nitrotoluene (72 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (65:30:5) as an 
eluent to afford the title compound as a pale-brown amorphous solid (88 mg, 81%). 1H NMR (400 
MHz, CDCl3): δ 9.15 (s, 1 H), 7.80 (d, J = 8.2 Hz, 2 H), 7.67 (d, J = 8.3 Hz, 2 H), 7.19 (d, J = 8.2 Hz, 2 
H), 7.14 (d, J = 8.2 Hz, 2 H), 3.54 (q, J = 6.8 Hz, 2 H), 3.17 54 (q, J = 6.7 Hz, 2 H), 2.33 (s, 3 H), 1.24 
(t, J = 6.5 Hz, 3 H), 1.06 t, J = 6.5 Hz, 3 H). 13C NMR (100 MHz, CDCl3): δ 170.8, 165.6, 139.4, 
136.0, 134.0, 129.4, 127.7, 126.1, 120.6, 43.4, 39.6, 21.0, 14.2, 13.0. HRMS (ESI): Calcd for 
C19H23N2O2 [M+H]: 311.1760; Found: 311.1771. 
 
 
 
 
N-(3-Methoxy-4-methylphenyl)-4-(trifluoromethyl)benzamide (4e). Following the general 
procedure B, the title compound was prepared using 4-bromobenzotrifluoride (79 mg) and 2-methoxy-
4-nitrotoluene (88 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title compound as a pale brown amorphous 
solid (88 mg, 81%). 1H NMR (400 MHz, CD2Cl2): δ 8.07 (s, 1 H), 7.97 (d, J = 7.3 Hz, 2 H), 7.73 (d, J 
= 7.3 Hz, 2 H), 7.36 (s, 1 H), 7.10 (d, J = 7.5 Hz, 1 H), 7.02 (d, J = 6.7 Hz, 1 H), 3.82 (s, 3 H), 2.19 (s, 
3 H). 13C NMR (100 MHz, CD2Cl2): δ 164.7, 158.5, 139.0, 137.2, 133.5 (q, 2JCF = 32.5 Hz), 130.9, 
128.0, 126.2 (q, 3JCF = 3.7 Hz), 124.3 (q, 1JCF = 270.7 Hz), 123.7, 112.4, 103.7, 55.8, 15.9. HRMS 
(ESI): Calcd for C16H15F3NO2 [M+H]: 310.1055; Found: 310.1063. 
 
 
 
 
N-(Benzo[d][1,3]dioxol-5-yl)-3-(dimethylamino)benzamide (4f). Following the general procedure B, 
the title compound was prepared using 4-bromo-N,N-diethylbenzamide (70 mg) and 5-
nitrobenzo[d][1,3]dioxole (88 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title compound as an off-white amorphous 
solid (70 mg, 71%). 1H NMR (400 MHz, CDCl3): δ 7.99 (s, 1 H), 7.34 (d, J = 1.8 Hz, 1 H), 7.26-7.21 
(ovrlp, 2 H), 7.04 (d, J = 7.5 Hz, 1 H), 6.90 (dd, J = 8.3 Hz, J = 2.0 Hz, 1 H), 6.83 (d, J = 8.2 Hz, J = 
2.4 Hz, 1 H), 6.73 (d, J = 8.3 Hz, 1 H), 5.96 (s, 2 H), 2.96 (s, 9 H). 13C NMR (100 MHz, CDCl3): δ 
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166.7, 150.8, 147.8, 144.4, 135.8, 132.5, 129.3, 115.5, 114.0, 113.6, 111.4, 108.1, 103.3, 101.3, 40.5. 
HRMS (ESI): Calcd for C16H17N2O3 [M+H]: 285.1239; Found: 285.1239. 
 
 
 
 
N-(4-Methoxyphenyl)-3-propionylbenzamide (4g). Following the general procedure B, the title 
compound was prepared using 1-(4-bromophenyl)propan-1-one (75 mg) and 4-nitroanisole (80 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a brown amorphous solid (50 mg, 51%). 1H NMR (400 MHz, 
CDCl3): δ 8.41 (s, 1 H), 8.11-8.06 (ovrlp, 2 H), 8.03 (s, 1 H), 7.59-7.52 (ovrlp, 3 H), 6.90 (d, J = 8.4 
Hz, 2 H), 3.81 (s, 3 H), 3.04 (q, J = 7.0 Hz, 2 H), 1.23 (t, J = 7.0 Hz, 3 H). 13C NMR (100 MHz, 
CDCl3): δ 200.2, 165.0, 156.9, 137.2, 135.6, 131.7, 131.0, 130.9, 129.2, 126.3, 122.4, 114.3, 55.6, 32.1, 
8.2. HRMS (ESI): Calcd for C17H18NO3 [M+H]: 284.1287; Found: 284.1289. 
 
 
 
 
N-(9H-Fluoren-2-yl)-3-(trifluoromethyl)benzamide (4h). Following the general procedure B, the 
title compound was prepared using 3-bromobenzotrifluoride (79 mg) and 2-nitro-9H-fluorene (111 
mg). The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an 
eluent to afford the title compound as a pale brown amorphous solid (62 mg, 50%). 1H NMR (400 
MHz, CDCl3): δ 8.15 (s, 1 H), 8.09 (d, J = 7.8 Hz, 1 H), 8.02 (s, 1 H), 7.93 (s, 1 H), 7.83 (d, J = 7.8 Hz, 
1 H), 7.79-7.75 (ovrlp, 2 H), 7.65 (t, J = 7.8 Hz, 1 H), 7.56-7.50 (ovrlp, 2 H), 7.38 (t, J = 7.4 Hz, 1 H), 
7.30 (td, J = 7.4 Hz, J = 1.1 Hz, 1 H), 3.94 (s, 2 H). 13C NMR (100 MHz, CDCl3): δ 164.4, 144.6, 
143.4, 141.3, 139.0, 136.4, 136.1, 131.6 (q, 2JCF = 32.7 Hz), 130.5, 129.7, 128.6 (q, 3JCF = 3.6 Hz), 
127.0, 126.7, 125.2, 124.1 (q, 3JCF = 3.8 Hz), 122.7 (q, 1JCF = 270.8 Hz), 120.4, 119.8, 119.3, 117.5, 
37.2. HRMS (ESI): Calcd for C21H15F3NO [M+H]: 354.1106; Found: 354.1109. 
 
 
 
 
N-(3-(Trifluoromethyl)phenyl)-2-naphthamide (4i).16 Following the general procedure B, the title 
compound was prepared using 2-bromonaphthalene (73 mg), 3-nitrobenzotrifluoride (100 mg), 
Ni(glyme)Cl2 (15 mol %, 11.6 mg), and L4 (15 mol %, 14.1 mg). The crude product was purified by 
preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as an 
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off-write amorphous solid (64 mg, 58%). 1H NMR (400 MHz, CDCl3): δ 8.33 (s, 1 H), 8.27 (s, 1 H), 
7.98 (s, 1 H), 7.93-7.85 (ovrlp, 5 H), 7.60-7.52 (ovrlp, 2 H), 7.47 (t, J = 8.0 Hz, 1 H), 7.40 (d, J = 7.8 
Hz, 1 H). 13C NMR (100 MHz, CDCl3): δ 138.7, 135.1, 132.7, 131.7, 131.6 (q, 2JCF = 32.3 Hz), 129.8, 
129.1, 129.0, 128.3, 128.1, 128.0, 127.8, 127.2 (q, 1JCF = 270.6 Hz), 123.52, 123.46 (q, 4JCF = 0.8 Hz), 
121.2 (q, 3JCF = 3.8 Hz), 117.1 (q, 3JCF = 4.0 Hz).  
 
 
 
 
N-(4-(tert-Butyl)phenyl)quinoline-3-carboxamide (4j). Following the general procedure B, the title 
compound was prepared using 3-bromoquinoline (73 mg) and 1-(tert-butyl)-4-nitrobenzene (95 mg). 
The crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an 
eluent to afford the title compound as a off-white amorphous solid (85 mg, 80%). 1H NMR (400 MHz, 
CDCl3): δ 9.35 (s, 1 H), 8.65 (s, 1 H), 8.34 (s, 1 H), 8.12 (d, J = 8.4 Hz, 1 H), 7.86 (d, J = 7.9 Hz, 1 H), 
7.79 (t, J = 7.3 Hz, 1 H), 7.64-7.56 (ovrlp, 3 H), 7.39 (d, J = 8.4 Hz, 2 H), 1.32 (s, 9 H). 13C NMR (100 
MHz, CDCl3): δ 164.1, 149.2, 148.24, 148.19, 136.1, 135.1, 131.6, 129.4, 128.9, 127.8, 127.0, 126.1, 
120.5, 34.6, 31.5. HRMS (ESI): Calcd for C20H21N2O [M+H]: 305.1654; Found: 305.1649. 
 
 
 
 
1-Benzyl-N-(4-(tert-butyl)phenyl)-1H-indole-5-carboxamide (4k). Following the general procedure 
B, the title compound was prepared using 1-benzyl-5-bromo-1H-indole (100 mg) and 1-(tert-butyl)-4-
nitrobenzene (95 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a brown amorphous solid 
(57 mg, 43%). 1H NMR (400 MHz, CDCl3): δ 8.09 (d, J = 0.9 Hz, 1 H), 7.87 (s, 1 H), 7.59 (dd, J = 8.6 
Hz, J = 1.4 Hz, 1 H), 7.49 (d, J = 8.6 Hz, 2 H), 7.27 (d, J = 8.6 Hz, 2 H), 7.21-7.17 (ovrlp, 4 H), 7.09 
(d, J = 3.1 Hz, 1 H), 7.00-6.97 (ovrlp, 2 H), 6.52 (d, J = 3.1 Hz, 1 H), 5.22 (s, 2 H), 1.23 (s, 9 H). 13C 
NMR (100 MHz, CDCl3): δ 166.9, 147.1, 138.1, 137.0, 135.9, 130.0, 129.0, 128.5, 127.9, 126.83, 
126.77, 125.9, 121.0, 120.8, 120.1, 109.9, 103.1, 50.4, 34.5, 31.5. HRMS (ESI): Calcd for C26H27N2O 
[M+H]: 383.2123; Found: 383.2115. 
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N-(4-methoxyphenyl)-2-methyl-2H-indazole-5-carboxamide (4l). Following the general procedure B, 
the title compound was prepared using 5-bromo-2-methyl-2H-indazole (74 mg), 4-nitroanisole (120 
mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), and L4 (15 mol %, 11.4 mg). The crude product was purified 
by preparative TLC using hexanes/CH2Cl2 (90:10) as an eluent to afford the title compound as an off-
white amorphous solid (53 mg, 53%). 1H NMR (400 MHz, DMSO-d6): δ 10.09 (s, 1 H), 8.57 (s, 1 H), 
8.42 (s, 1 H), 7.78 (d, J = 9.1 Hz, 1 H), 7.70-7.65 (ovrlp, 3 H), 6.93 (d, J = 8.5 Hz, 2 H), 4.21 (s, 3 H), 
3.75 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 165.5, 155.4, 148.8, 132.5, 127.7, 126.7, 124.5, 
121.9, 121.5, 120.8, 116.5, 113.7, 55.2, 40.2. HRMS (ESI): Calcd for C16H16N3O2 [M+H]: 282.1242; 
Found: 282.1247. 
 
 
 
 
N-(4-(p-Tolyloxy)phenyl)benzofuran-5-carboxamide (4m). Following the general procedure B, the 
title compound was prepared using 5-bromobenzofuran (69 mg), 1-methyl-4-(4-nitrophenoxy)benzene 
(120 mg), Ni(glyme)Cl2 (15 mol %, 11.6 mg), and L4 (15 mol %, 11.4 mg). The crude product was 
purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title 
compound as a pale-brown amorphous solid (55 mg, 46%). 1H NMR (400 MHz. CDCl3): δ 8.14 (s, 1 
H), 7.94 (s, 1 H), 7.81 (d, J = 8.4 Hz, 1 H), 7.70 (d, J = 0.8 Hz, 1 H), 7.59-7.54 (ovrlp, 3 H), 7.13 (d, J 
= 8.0 Hz, 2 H), 6.99 (d, J = 8.7 Hz, 2 H), 6.91 (d, J = 8.2 Hz, 2 H), 6.83 (s, 1 H), 2.33 (s, 9 H). 13C 
NMR (100 MHz. CDCl3): δ 166.1, 156.8, 155.1, 154.4, 146.6, 133.3, 132.9, 130.4, 130.2, 127.9, 123.6, 
122.2, 120.9, 119.2, 118.9, 111.8, 107.1, 20.8. HRMS (ESI): Calcd for C22H18NO3 [M+H]: 344.1287; 
Found: 344.1278. 
 
 
 
 
N-(4-(tert-Butyl)phenyl)-9-ethyl-9H-carbazole-3-carboxamide (4n). Following the general 
procedure B, the title compound was prepared using 3-bromo-9-ethyl-9H-carbazole (96 mg) and 1-
(tert-butyl)-4-nitrobenzene (95 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a brown amorphous solid 
(91 mg, 70%). 1H NMR (400 MHz. CDCl3): δ 8.59 (s, 1 H), 8.11 (s, 1 H), 8.07 (d, J = 7.6 Hz, 1 H), 
7.95 (d, J = 8.2 Hz, 1 H), 7.64 (d, J = 8.0 Hz, 2 H), 7.49 (t, J = 7.4 Hz, 1 H), 7.43-7.31 (ovlp, 4 H), 7.24 
(t, J = 7.9 Hz, 1 H), 4.30 (q, J = 7.6 Hz, 2 H), 1.39 (t, J = 6.8 Hz, 3 H), 1.33 (s, 9 H). 13C NMR (100 
MHz. CDCl3): δ 166.6, 147.3, 141.9, 140.7, 136.0, 126.5, 126.0, 125.6, 124.9, 123.0, 122.9, 120.8, 
120.2, 120.1, 119.8, 109.0, 108.4, 37.9, 34.5, 31.5, 13.9. HRMS (ESI): Calcd for C25H27N2O [M+H]: 
371.2123; Found: 371.2118. 
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N-([1,1'-Biphenyl]-3-yl)dibenzo[b,d]thiophene-3-carboxamide (4o). Following the general 
procedure B, the title compound was prepared using 3-bromodibenzo[b,d]thiophene (92 mg) and 3-
nitro-1,1'-biphenyl (105 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (85:10:5) as an eluent to afford the title compound as a off-white amorphous 
solid (110 mg, 83%). 1H NMR (400 MHz, DMSO-d6): δ 10.53 (s, 1 H), 9.03 (s, 1 H), 8.51-8.46 (m, 1 
H), 8.22-8.14 (ovrlp, 3 H), 8.10-8.06 (m, 1 H), 7.92 (d, J = 8.0 Hz, 1 H), 7.69 (d, J = 7.4 Hz, 2 H), 7.61-
7.55 (ovrlp, 2 H), 7.52-7.46 (ovrlp, 3 H), 7.44-7.37 (ovrlp, 2 H). 13C NMR (100 MHz, DMSO-d6): δ 
165.4, 141.9, 140.7, 140.2, 139.8, 139.1, 134.9, 134.8, 131.5, 129.3, 129.0, 127.6, 126.6, 126.2, 125.1, 
123.2, 123.0, 122.3, 122.0, 121.3, 119.4, 118.7. HRMS (ESI): Calcd for C25H18NOS [M+H]: 380.1109; 
Found: 380.1105. 
 
 
 
 
 (E)-N-(2,5-Dimethoxyphenyl)-3-(4-fluorophenyl)acrylamide (4p). Following the general procedure 
B, the title compound was prepared using (E)-1-(2-bromovinyl)-4-fluorobenzene (70 mg) and 1,4-
dimethoxy-2-nitrobenzene (96 mg). The crude product was purified by preparative TLC using 
hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to afford the title compound as a brown amorphous solid 
(46 mg, 44%). 1H NMR (400 MHz, CDCl3): δ 8.27 (s, 1 H), 7.97 (s, 1 H), 7.70 (d, J = 15.5 Hz, 1 H), 
7.53 (dd, 3JHH = 8.6 Hz, 4JHF = 5.4 Hz, 2 H), 7.07 (dd, 3JHH = 8.6 Hz, 3JHF = 8.6 Hz, 2 H), 6.81 (d, J = 
8.9 Hz, 1 H), 6.60 (dd, J = 8.9 Hz, J = 3.0 Hz, 1 H), 6.51 (d, J = 15.5 Hz, 1 H), 3.87 (s, 3 H), 3.81 (s, 3 
H). 13C NMR (100 MHz, CDCl3): δ 163.8 (d, 1JCF = 249.2 Hz), 163.7, 154.1, 142.2, 141.0, 131.1, 
129.9 (d, 3JCF = 8.4 Hz), 128.6, 121.1 (d, 4JCF = 1.6 Hz), 116.1 (d, 2JCF = 21.8 Hz), 110.8, 109.0, 106.1, 
56.4, 55.9.  HRMS (ESI): Calcd for C17H17FNO3 [M+H]: 302.1192; Found: 302.1194. 
 
 
 
 
 
N-(4-Chloro-3-methoxyphenyl)picolinamide (5).17 Following the general procedure A, the title 
compound was prepared using 2-iodopyridine (72 mg), 2-chloro-5-nitroanisole (99 mg), Ni(glyme)Cl2 
(15 mol %, 11.6 mg), L1 (15 mol %, 14.1 mg), Co2(CO)8 (1 equiv, 120 mg), and DMF (1.4 mL). The 
crude product was purified by preparative TLC using hexanes/EtOAc/CH2Cl2 (75:20:5) as an eluent to 
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afford the title compound as an off-white amorphous solid (58 mg, 63%). 1H NMR (400 MHz, DMSO-
d6): δ 10.76 (s, 1 H), 8.75 (d, J = 4.6 Hz, 1 H), 8.16 (d, J = 7.8 Hz, 1 H), 8.08 (td, J = 7.6 Hz, J = 4.0 
Hz, 1 H), 7.84 (d, J = 2.2 Hz, 1 H), 7.69 (ddd, J = 7.4 Hz, J = 4.8 Hz, J = 1.0 Hz, 1 H), 7.63 (dd, J = 8.6 
Hz, J = 2.2 Hz, 1 H), 7.39 (d, J = 8.6 Hz, 1 H), 3.86 (s, 3 H). 13C NMR (100 MHz, DMSO-d6): δ 162.6, 
154.4, 149.6, 148.4, 138.6, 138.2, 129.6, 127.1, 122.4, 115.4, 112.8, 105.1, 55.9.  
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